Shares of healthcare solutions provider Solventum (NYSESOLV)
fell 6.5% in the morning session after the company reported weak fourth quarter results: its full-year EPS guidance missed. On the other hand, Solventum narrowly topped analysts' organic revenue expectations, with organic sales rising 2.3% year-on-year, led by growth in its MedSurg and Dental Solutions segments. Looking ahead, the company expects 1% to 2% organic revenue growth in 2025 but will update its guidance following the sale of its Purification & Filtration segment. Overall, we think this was a mixed quarter. The areas below expectations seem to be driving the move.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Healthcare solutions provider Solventum (NYSESOLV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 1.9% year on year to $2.07 billion. Its non-GAAP profit of $1.41 per share was 7.8% above analysts’ consensus estimates.
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSESOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on Solventum’s recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc NYSE: TMONYSETMO)
Solventum shares are trading higher Tuesday after the company announced it will sell its purification and filtration business to Thermo Fisher for $4.1 billion in cash.
Thermo Fisher will acquire Solventum's Purification & Filtration business for $4.1 billion, expanding its bioproduction portfolio with expected long-term growth.
Solventum has had an impressive run over the past six months as its shares have beaten the S&P 500 by 15.9%. The stock now trades at $74.24, marking a 24.9% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics.
Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company
Trian Fund Management reshaped its portfolio in Q3. The moves come as Donald Trump's election victory is expected to bring significant economic policy shifts.
